Ash 2021 preview – as competition grows Autolus monetises
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
J&J breathes some more life into plamotamab and CD28
Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
Cytokine interest shows no sign of waning
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
Amgen doubles down on bispecifics, courtesy of Teneobio
Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
Ash 2020 – IGM averts disaster, but competition looms
Sellside firefighting has saved the day for IGM, but Ash hears of some pretty potent anti-CD20 competition for the company.
